A detailed history of Charles Schwab Investment Management Inc transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 442,748 shares of DAWN stock, worth $6.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
442,748
Previous 457,652 3.26%
Holding current value
$6.27 Million
Previous $7.56 Million 19.3%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$12.03 - $17.69 $179,295 - $263,651
-14,904 Reduced 3.26%
442,748 $6.1 Million
Q1 2024

May 08, 2024

BUY
$13.56 - $17.46 $63,976 - $82,376
4,718 Added 1.04%
457,652 $7.56 Million
Q4 2023

Feb 06, 2024

BUY
$9.68 - $15.37 $56,105 - $89,084
5,796 Added 1.3%
452,934 $6.61 Million
Q3 2023

Nov 08, 2023

BUY
$11.22 - $14.86 $1.4 Million - $1.86 Million
125,050 Added 38.82%
447,138 $5.49 Million
Q2 2023

Aug 09, 2023

BUY
$11.74 - $14.47 $1.4 Million - $1.73 Million
119,421 Added 58.92%
322,088 $3.85 Million
Q1 2023

May 11, 2023

SELL
$12.75 - $23.41 $15,784 - $28,981
-1,238 Reduced 0.61%
202,667 $2.71 Million
Q4 2022

Feb 13, 2023

BUY
$18.77 - $22.0 $92,967 - $108,966
4,953 Added 2.49%
203,905 $4.39 Million
Q3 2022

Nov 14, 2022

BUY
$16.44 - $26.57 $754,743 - $1.22 Million
45,909 Added 30.0%
198,952 $3.99 Million
Q2 2022

Aug 15, 2022

BUY
$5.72 - $17.9 $280,331 - $877,261
49,009 Added 47.11%
153,043 $2.74 Million
Q1 2022

May 13, 2022

BUY
$9.12 - $17.47 $254,137 - $486,819
27,866 Added 36.58%
104,034 $1.03 Million
Q4 2021

Feb 11, 2022

BUY
$15.65 - $26.33 $14,742 - $24,802
942 Added 1.25%
76,168 $1.28 Million
Q3 2021

Nov 16, 2021

BUY
$20.0 - $27.92 $1.5 Million - $2.1 Million
75,226 New
75,226 $1.79 Million

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $1.04B
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.